[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629575":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":35,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":61,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Xiaoyao Li, PhD","CONTACT","+86 01088322295","fwlxy2015@163.com",[15],{"facility":16,"status":7,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Beilishi Road 167","Beijing","Beijing Municipality","100037","China","CN",{"type":23,"coordinates":24},"Point",[25,26],116.39723,39.9075,{"lat":26,"lon":25},[29,33],{"name":30,"role":11,"phone":31,"phoneExt":7,"email":32},"NCCD","01088822295","ncrc@fuwai.com",{"name":10,"role":34,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":34,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Xiaoyao Li","Arrhythmia Center Attending Physician","100629575","skeletal-muscle-multi-omics-analysis-and-risk-tailoring-in-sudden-cardiac-death-100629575",false,"NCT07476456","Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death","Development and Implementation of an Artificial Intelligence-Driven Multimodal Skeletal Muscle Feature Fusion Model for Risk Prediction of Sudden Cardiac Death in Patients With Implantable Cardioverter-Defibrillators: The SMART-SCD Study.","SMART-SCD","Inclusion Criteria:\n\n* Undergoing first-time ICD implantation (including cardiac resynchronization therapy defibrillator, CRT-D implantation);\n* Completed multi-dimensional sarcopenia assessment at baseline;\n* Willing to receive prospective follow-up and signed the informed consent form (ICF)\n\nExclusion Criteria:\n\n* History of valvular heart disease (e.g., mitral stenosis, history of heart valve replacement or valvuloplasty, etc.);\n* Implanted ICD type is subcutaneous ICD (S-ICD) or extra-vascular ICD (EV-ICD);\n* Concomitant comorbidities affecting muscle metabolism, such as malignant tumors, severe liver or kidney disease, etc.","ALL","18 Years",{"count":49,"type":50},421,"ESTIMATED","OBSERVATIONAL","This study is designed as a prospective, single-center, observational cohort study (the SMART-SCD Study, full name: Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death), which enrolls high-risk populations meeting the criteria for implantable cardioverter defibrillator (ICD) implantation.\n\nThe research focuses on the mechanistic association between skeletal muscle metabolic disorders and ventricular arrhythmia (VA) as well as sudden cardiac death (SCD), and aims to construct a \"muscle-heart crosstalk\" risk early warning system through integration of multimodal skeletal muscle data. We will systematically collect the following data:\n\nBaseline handgrip strength measurement (Biomi-h500+X5); Functional diagnosis and phenotyping of sarcopenia conducted via the InBody 270 body composition analyzer; Non-contrast chest and abdominal computed tomography (CT) images (to extract novel imaging phenotypes including skeletal muscle density at the T12 vertebra level, intermuscular adipose tissue, subcutaneous adipose tissue, etc.); Serum biomarkers (GDF-8, Irisin, IL-6); Metabolomics data of skeletal muscle tissue from the ICD pocket (lipid\u002Fenergy metabolism profiles detected via the UPLC-QTOF\u002FMS platform); Ambulatory electrocardiographic data. All treatment and intervention regimens for patients will be independently formulated by clinicians in accordance with clinical guidelines, and the study itself does not involve any intervention measures. Prospective follow-up will be conducted at 3\u002F6\u002F12 months after ICD implantation. The primary endpoint is composite ventricular arrhythmia events (including SCD, appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia\u002Fventricular fibrillation), and the secondary endpoint is all-cause mortality.\n\nThrough the above prospective cohort study, we will integrate multimodal data including novel CT imaging phenotypes of skeletal muscle, metabolomics profiles and functional phenotyping of sarcopenia using artificial intelligence techniques, so as to construct a precision prediction model for SCD, screen novel CT imaging phenotypes of sarcopenia and myogenic metabolites, and finally establish a generalizable SCD risk assessment tool and individualized intervention strategies.",[54],"Sudden Cardiac Death",[56,57,58,59,60],"Sarcopenia","Skeletal Muscle Metabolism","Ventricular Arrhythmia","Multimodal Predictive Model","Sudden cardiac death","NOT_YET_RECRUITING","2026-03-12",{"date":64,"type":65},"2026-03-17","ACTUAL",{"date":67,"type":50},"2026-03-16",{"date":69,"type":50},"2028-06-30",{"name":5,"class":6},1]